Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Last trade$77.87
Day change-$0.81 (-1.03%)
Day range$76.31 – $78.72
Volume212,311
Market cap$3.88B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.88B
Price / earnings
—
Price / book
37.29×
Price / sales
5.69×
EV / sales
5.59×
EV / EBITDA
-5.46×
Profitability
Earnings per share
-$14.25
Return on assets
-139.01%
Return on equity
-675.49%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.7×
Current ratio
1.96×
Quick ratio
1.94×
Cash ratio
0.6×
Cash flow
Price / cash flow
77.74×
Price / free cash flow
119.58×
Free cash flow
$32.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TARS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$194.57M
$173.91M
$162.05M
$151.67M
$118.7M
$102.66M
$78.34M
$66.41M
Cost of revenue
$13.89M
$12.11M
$9.4M
$10.93M
$8.31M
$6.24M
$5.21M
$4.93M
Gross profit
$180.68M
$161.8M
$152.66M
$140.74M
$110.39M
$96.42M
$73.12M
$61.48M
Selling, general and administrative
$168.02M
$150.7M
$136.43M
$130.68M
$108.63M
$103.01M
$85M
$69.03M
Research and development
$676.37M
$31.01M
$22.35M
$18.04M
$16.28M
$15.59M
$14.41M
$16.87M
Total operating expenses
$842.77M
$181.71M
$158.78M
$148.72M
$124.92M
$118.61M
$99.4M
$85.9M
Operating income
-$662.09M
-$19.91M
-$6.12M
-$7.98M
-$14.53M
-$22.18M
-$26.28M
-$24.42M
Interest expense
-$2.19M
-$2.16M
-$2.13M
-$2.21M
-$2.27M
-$2.24M
-$2.21M
-$2.31M
Income before taxes
-$663.69M
-$15.84M
-$4.62M
-$6.31M
-$12.59M
-$20.34M
-$25.12M
-$23.11M
Income taxes
$4.64M
$2.72M
$2.35M
$2.06M
$0
$0
$0
$0
Net income
-$668.33M
-$18.55M
-$6.97M
-$8.37M
-$12.59M
-$20.34M
-$25.12M
-$23.11M
Net income attributable to common shareholders
-$668.33M
-$18.55M
-$7.65M
-$8.17M
-$12.59M
-$20.34M
-$25.21M
-$22.93M
EBITDA
-$661.07M
-$18.06M
-$6.53M
-$13.02M
-$14.07M
-$20.42M
-$27.13M
-$28.2M
Basic earnings per share
-$14.40
-$0.43
-$0.16
-$0.19
-$0.30
-$0.48
-$0.64
-$0.59
Diluted earnings per share
-$14.40
-$0.43
-$0.16
-$0.19
-$0.30
-$0.48
-$0.64
-$0.59
Recent news
Company coverage with links to the original publishers.
Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.
Tarsus Pharmaceuticals reported a Q3 loss of $0.78 per share, beating consensus estimates of $1.43 loss by 45.46%. Revenue reached $194.57 million, surpassing estimates by 3.06% and up 64% year-over-year. The company has topped revenue estimates four times in the last four quarters and holds a Zacks Rank #2 (Buy) rating, though shares have underperformed the S&P 500 by 20.7% year-to-date.
Tarsus Pharmaceuticals (TARS) has gained 2.5% over the past four weeks and closed at $74.85. Wall Street analysts project a mean price target of $97.89, indicating potential upside of 30.8%. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions with the consensus estimate increasing 3.1% over the past month. However, the article cautions that price targets alone should not be the sole basis for investment decisions.
Harmony Biosciences is expected to report Q3 2026 earnings on November 4, with Wall Street anticipating 14.9% YoY EPS growth to $1.00 per share and 13.1% revenue growth to $270.87 million. However, a negative Earnings ESP of -12.00% combined with recent downward estimate revisions suggests the stock may not beat consensus expectations, despite carrying a Zacks Rank #1 rating.
Tarsus Pharmaceuticals is expected to report a quarterly loss of $1.43 per share (down 376.7% YoY) with revenues of $188.8 million (up 59.1% YoY) for Q3 2026. The company has a negative Earnings ESP of -40.31% combined with a Zacks Rank #2, making it unlikely to beat consensus estimates. The company has a mixed earnings surprise history, beating estimates in 2 of the last 4 quarters.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.